Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20179215rdf:typepubmed:Citationlld:pubmed
pubmed-article:20179215lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1414864lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1522480lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1427801lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C0021044lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1516048lld:lifeskim
pubmed-article:20179215lifeskim:mentionsumls-concept:C1510438lld:lifeskim
pubmed-article:20179215pubmed:issue5lld:pubmed
pubmed-article:20179215pubmed:dateCreated2010-3-2lld:pubmed
pubmed-article:20179215pubmed:abstractTextIn vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) is strongly predicted by the expression of the O-glycosylation enzymes GALNT14 in non-small cell lung cancer (NSCLC) cell lines (among others) and of FUT3/6 in colorectal cancer (CRC) cell lines. We developed immunohistochemistry (IHC) assays that measure GALNT14 and FUT3/6 levels in archival formalin-fixed, paraffin-embedded human tumor tissue to determine marker prevalence in NSCLC and CRC tissue and to enable the future examination of these markers in clinical trials.lld:pubmed
pubmed-article:20179215pubmed:languageenglld:pubmed
pubmed-article:20179215pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:citationSubsetIMlld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20179215pubmed:statusMEDLINElld:pubmed
pubmed-article:20179215pubmed:monthMarlld:pubmed
pubmed-article:20179215pubmed:issn1078-0432lld:pubmed
pubmed-article:20179215pubmed:authorpubmed-author:WagnerKlausKlld:pubmed
pubmed-article:20179215pubmed:authorpubmed-author:AshkenaziAviAlld:pubmed
pubmed-article:20179215pubmed:authorpubmed-author:SternHoward...lld:pubmed
pubmed-article:20179215pubmed:authorpubmed-author:AmlerLukasLlld:pubmed
pubmed-article:20179215pubmed:authorpubmed-author:PadillaMaryMlld:pubmed
pubmed-article:20179215pubmed:issnTypePrintlld:pubmed
pubmed-article:20179215pubmed:day1lld:pubmed
pubmed-article:20179215pubmed:volume16lld:pubmed
pubmed-article:20179215pubmed:ownerNLMlld:pubmed
pubmed-article:20179215pubmed:authorsCompleteYlld:pubmed
pubmed-article:20179215pubmed:pagination1587-96lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:meshHeadingpubmed-meshheading:20179215...lld:pubmed
pubmed-article:20179215pubmed:year2010lld:pubmed
pubmed-article:20179215pubmed:articleTitleDevelopment of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.lld:pubmed
pubmed-article:20179215pubmed:affiliationDepartments of Research Pathology, Development Oncology Diagnostics, and Molecular Oncology, Genentech, Inc, South San Francisco, California, USA.lld:pubmed
pubmed-article:20179215pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20179215pubmed:publicationTypeValidation Studieslld:pubmed
entrez-gene:2525entrezgene:pubmedpubmed-article:20179215lld:entrezgene
entrez-gene:2528entrezgene:pubmedpubmed-article:20179215lld:entrezgene
entrez-gene:79623entrezgene:pubmedpubmed-article:20179215lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20179215lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20179215lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20179215lld:entrezgene